In an effort to simplify the science behind our ambition to ‘drug the undruggable’, this podcast draws back the curtain on cancer research and takes a look at its complex inner workings. Hosted by Sebastian Hermelin (co-founder of the War On Cancer app), each episode welcomes a new expert guest who takes the listener through one of the many stages of cancer research and drug development; from early discovery efforts, through to clinical trials and drug approval.
All content for Taking Cancer On is the property of Boehringer Ingelheim and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In an effort to simplify the science behind our ambition to ‘drug the undruggable’, this podcast draws back the curtain on cancer research and takes a look at its complex inner workings. Hosted by Sebastian Hermelin (co-founder of the War On Cancer app), each episode welcomes a new expert guest who takes the listener through one of the many stages of cancer research and drug development; from early discovery efforts, through to clinical trials and drug approval.
Expert Guests: Jose Barrueco, M.D. Ph.D. and Petra Blum, M.D. Ph.D., both leading Global Clinical Development teams in Oncology at Boehringer Ingelheim.
In this episode, Jose and Petra discuss cancer immunology and explain what it takes to develop cancer immunotherapies. How can the immune system be used to treat cancer? What is Boehringer Ingelheim contributing to this field? What is the future of cancer immunotherapy? Listen to this episode to find out more!
Taking Cancer On
In an effort to simplify the science behind our ambition to ‘drug the undruggable’, this podcast draws back the curtain on cancer research and takes a look at its complex inner workings. Hosted by Sebastian Hermelin (co-founder of the War On Cancer app), each episode welcomes a new expert guest who takes the listener through one of the many stages of cancer research and drug development; from early discovery efforts, through to clinical trials and drug approval.
